Abstract
Loss of the DNA-dependent protein kinase (DNA-PK) results in increased sensitivity to ionizing radiation due to inefficient repair of DNA double-strand breaks. Overexpression of DNA-PK in tumor cells conversely results in resistance to ionizing radiation. It is therefore possible that inhibition of DNA-PK will enhance the preferential killing of tumor cells by radiotherapy. Available inhibitors of DNA-PK, like wortmannin, are cytotoxic and stop the cell cycle because they inhibit phoshatidylinositol-3-kinases at 100-fold lower concentrations required to inhibit DNA-PK. In an effort to develop a specific DNA-PK inhibitor, we have characterized SU11752, from a three-substituted indolin-2-ones library. SU11752 and wortmannin were equally potent inhibitors of DNA-PK. In contrast, inhibition of the phoshatidylinositol-3-kinase p110γ required 500-fold higher concentration of SU11752. Thus, SU11752 was a more selective inhibitor of DNA-PK than wortmannin. Inhibition kinetics and a direct assay for ATP binding showed that SU11752 inhibited DNA-PK by competing with ATP. SU11752 inhibited DNA double-strand break repair in cells and gave rise to a five-fold sensitization to ionizing radiation. At concentrations of SU11752 that inhibited DNA repair, cell cycle progression was still normal and ATM kinase activity was not inhibited. We conclude that SU11752 defines a new class of drugs that may serve as a starting point for the development of specific DNA-PK inhibitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- DSB:
-
DNA double-stranded break
- DNA-PK:
-
DNA-dependent protein kinase
- DNA-PKcs:
-
the catalytic subunit of DNA-PK
- ssDNA:
-
single-stranded DNA
- dsDNA:
-
double-stranded DNA
- PI3-kinase:
-
phosphatidylinositol-3 kinase
- ATM:
-
ataxia telangiectasia mutated
- ATR:
-
ATM and rad3-related
- PBS:
-
phosphate-buffered saline
- TBS:
-
Tris-buffered saline
References
Ahn JY, Schwarz JK, Piwnica-Worms H and Canman CE . (2000). Cancer Res., 60, 5934–5936.
Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y . (1998). Science, 281, 1674–1677.
Boulton S, Kyle S, Yalcintepe L and Durkacz BW . (1996). Carcinogenesis, 17, 2285–2290.
Burma S, Chen BP, Murphy M, Kurimasa A and Chen DJ . (2002). J. Biol. Chem., 276, 42462–42467.
Chan DW, Block W, Ye R, Khanna KK, Wold MS, Douglas P, Goodarzi AA, Pelley J, Taya Y, Lavin MF and Lees-Miller SP . (2000). J. Biol. Chem., 275, 7803–7810.
Chernikova SB, Wells RL and Elkind MM . (1999). Radiat. Res., 151, 159–166.
Christodoulopoulos G, Muller C, Salles B, Kazmi R and Panasci L . (1998). Cancer Res., 58, 1789–1792.
Collado M, Medema RH, Garcia-Cao I, Dubuisson ML, Barradas M, Glassford J, Rivas C, Burgering BM, Serrano M and Lam EW . (2000). J. Biol. Chem., 275, 21960–21968.
Cospedal R, Abedi H and Zachary I . (1999). Cardiovasc. Res., 41, 708–721.
Critchlow SE, Bowater RP and Jackson SP . (1997). Curr. Biol., 7, 588–598.
DiBiase SJ, Zeng ZC, Chen R, Hyslop T, Curran WJJ and Iliakis G . (2000). Cancer Res., 60, 1245–1253.
Durocher D and Jackson SP . (2001). Curr. Opin. Cell Biol., 13, 225–231.
Elmroth K, Mårtensson S, Ismail IH and Hammarsten O . (2003). DNA Repair (Amst.), 2, 363–374.
Elmroth K, Nygren J, Erkell LJ and Hultborn R . (2000). Int. J. Radiat. Biol., 76, 1501–1508.
Ferguson D, Sekiguchi J, Chang S, Frank K, Gao Y, DePinho R and Alt F . (2000). Proc. Natl. Acad. Sci. USA, 97, 6630–6633.
Frank K, Sekigushi J, Seidl K, Swat W, Rathbun G, Cheng H, Davidson L, Kangaloo L and Alt F . (1998). Nature, 396, 173–177.
Frit P, Canitrot Y, Muller C, Foray N, Calsou P, Marangoni E, Bourhis J and Salles B . (1999). Mol. Pharmacol., 56, 141–146.
Gao Y, Chaudhuri J, Zhu C, Davidson L, Weaver DT and Alt FW . (1998). Immunity, 9, 367–376.
Gell D and Jackson SP . (1999). Nucleic Acids Res., 27, 3494–3502.
Gottlieb T and Jackson SP . (1993). Cell, 72, 131–142.
Grawunder U, Zimmer D, Fugmann S, Schwartz K and Lieber M . (1998). Mol. Cell, 2, 477–484.
Gu Y, Jin S, Gao Y, Weaver D and Alt F . (1997). Proc. Natl. Acad. Sci. USA, 94, 8076–8081.
Hall-Jackson C, Cross D, Morries N and Smythe C . (2000). Oncogene, 18, 6707–6713.
Hammarsten O, DeFazio L and Chu G . (2000). J. Biol. Chem., 275, 1541–1550.
Hartley KO, Gell D, Smith GCM, Zhang H, Divecha N, Connelly MA, Admon A, Lees-Miller SP, Anderson CW and Jackson SP . (1995). Cell, 82, 849–856.
Hausdorff SF, Fingar DC, Morioka K, Garza LA, Whiteman EL, Summers SA and Birnbaum MJ . (1999). J. Biol. Chem., 274, 24677–24684.
Izzard RA, Jackson SP and Smith GC . (1999). Cancer Res., 59, 2581–2586.
Jackson SP . (2001). Biochem. Soc. Trans., 29 (Part 6), 655–661.
Kemp CJ, Vo K and Gurley KE . (1999). Carcinogenesis, 20, 2051–2056.
Khanna KK and Jackson SP . (2001). Nat. Genet., 27, 247–254.
Lees-Miller SP, Godbout R, Chan DW, Weinfeld M, Day RS, Barron GM and Allalunis-Turner J . (1995). Science, 267, 1183–1185.
Leuther KK, Hammarsten O, Kornberg RD and Chu G . (1999). EMBO J., 18, 1114–1123.
Ma Y, Pannicke U, Schwarz K and Lieber M . (2002). Cell, 108, 781–794.
Mårtensson S and Hammarsten O . (2002). J. Biol. Chem., 277, 3020–3029.
Mårtensson S, Nygren J, Osheroff N and Hammarsten O . (2003). Radiat. Res., 160, 291–301.
Matusoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K and Elledge S . (2000). Proc. Natl. Acad. Sci. USA, 97, 10389–10394.
Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T, Bozinovski S, de Montellano PR, Kemp BE and Pearson RB . (1999). Curr. Biol., 9, 845–848.
Mizuta R, Cheng HL, Gao Y and Alt FW . (1997). Int. Immunol., 9, 1607–1613.
Moshous D, Callebaut I, de Chasseval R, Corneo B, Cavazzana-Calvo M, Le Deist F, Tezcan I, Sanal O, Bertrand Y, Philippe N, Fischer A and de Villartay J . (2001). Cell, 105, 177–186.
Muller C, Christodoulopoulos G, Salles B and Panasci L . (1998). Blood, 92, 2213–2219.
Nias AHW . (1998). An Introduction to Radiobiology. John Wiley and Sons: New York, pp. 116–138.
Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M and Bonner WM . (2000). Curr. Biol., 10, 886–895.
Puglianiello A, Germani D, Rossi P and Cianfarani S . (2000). J. Endocrinol., 165, 123–131.
Rogakou EP, Boon C, Redon C and Bonner WM . (1999). J. Cell Biol., 146, 905–916.
Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM . (1998). J. Biol. Chem., 273, 5858–5868.
Rosenzweig K, Youmell M, Palayoor S and Price B . (1997). Clin. Cancer Res., 3, 1149–1156.
Rubin P and Siemann DW . (1993). Clinical Oncology: A Multidisciplinary Approach for Physicians and Students, Rubin P (ed). W.B. Saunders Company: Philadelphia, pp. 71–90.
Schwartz MF, Duong JK, Sun Z, Morrow JS, Pradhan D and Stern DF . (2002). Mol. Cell, 9, 1055–1065.
Shen H, Kauvar L and Tew KD . (1997). Oncol. Res., 9, 295–302.
Shiloh Y . (2001). Curr. Opin. Genet. Dev., 11, 71–77.
Shin EK, Perryman LE and Meek K . (1997). J. Immunol., 158, 3565–3569.
Sirzen F, Nilsson A, Zhivotovsky B and Lewensohn R . (1999). Eur. J. Cancer, 35, 111–116.
Stenerlow B, Karlsson KH, Cooper B and Rydberg B . (2003). Radiat. Res., 154, 502–510.
Stockley M, Clegg W, Fontana G, Golding BT, Martin N, Rigoreau LJ, Smith GC and Griffin RJ . (2001). Bioorg. Med. Chem. Lett., 11, 2837–2841.
Stoyanova S, Bulgarelli-Leva G, Kirsch C, Hanck T, Klinger R, Wetzker R and Wymann MP . (1997a). Biochem. J., 324, 489–495.
Stoyanova S, Bulgarelli-Leva G, Kirsch C, Hanck T, Klinger R, Wetzker R and Wymann MP . (1997b). Biochem. J., 324 (Part 2), 489–495.
Sun L, Tran N, Tang F, App H, Hirth P, McMahon G and Tang C . (1998). J. Med. Chem., 41, 2588–2603.
Taccioli GE, Amatucci AG, Beamish HJ, Gell D, Xiang XH, Torres Arzayus MI, Priestley A, Jackson SP, Marshak Rothstein A, Jeggo PA and Herrera VL . (1998). Immunity, 9, 355–366.
Take Y, Kumano M, Hamano Y, Fukatsu H, Teraoka H, Nishimura S and Okuyama A . (1995). Biochem. Biophys. Res. Commun., 251, 41–47.
Take Y, Kumano M, Teraoka H, Nishimura S and Okuyama A . (1996). Biochem. Biophys. Res. Commun., 221, 207–212.
Tounekti O, Kenani A, Foray N, Orlowski S and Mir LM . (2000). Br. J. Cancer, 84, 1272–1279.
Vaganay-Juery S, Muller C, Marangoni E, Abdulkarim B, Deutsch E, Lambin P, Calsou P, Eschwege F, Salles B, Joiner M and Bourhis J . (2000). Br. J. Cancer, 83, 514–518.
Walker J, Corpina R and Goldbreg J . (2001). Nature, 412, 607–614.
Wang H, Zeng Z, Bui T, DiBiase S, Qin W, Xia F, Powell S and Iliakis G . (2001). Cancer Res., 61, 270–277.
Wiler R, Leber R, Moore B, VanDyk L, Perryman L and Meek K . (1995). Proc. Natl. Acad. Sci. USA, 92, 11485–11489.
Williams CJ, Grandal I, Vesprini DJ, Wojtyra U, Danska JS and Guidos CJ . (2001). Mol. Cell. Biol., 21, 400–413.
Xu W, Liu L, Smith GCM and Charles IG . (2002). Nat. Cell Biol., 2, 339–345.
Zhao HJ, Hosoi Y, Miyachi H, Ishii K, Yoshida M, Nemoto K, Takai Y, Yamada S, Suzuki N and Ono T . (2000). Clin. Cancer Res., 6, 1073–1078.
Acknowledgements
We thank Matthias Wymann for supplying the anti-wortmannin antibody, and Per Elias and Henrik Zetterberg for careful reading of the manuscript. OH was supported by the Swedish Cancer Society, Swedish research council, King Gustav V Jubilee Clinic Cancer Research Foundation, and Sahlgren's University Hospital Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ismail, I., Mårtensson, S., Moshinsky, D. et al. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 23, 873–882 (2004). https://doi.org/10.1038/sj.onc.1207303
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207303
Keywords
This article is cited by
-
Combining carbon ion irradiation and non-homologous end-joining repair inhibitor NU7026 efficiently kills cancer cells
Radiation Oncology (2015)
-
DNA repair dysregulation from cancer driver to therapeutic target
Nature Reviews Cancer (2012)
-
High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde
Molecular Cancer (2011)
-
Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes
Oncogene (2010)
-
Clinical importance of DNA repair inhibitors in cancer therapy
memo - Magazine of European Medical Oncology (2009)